CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Royalties	$ 44,810	$ 47,765	$ 110,636	$ 160,633
Diagnostic services	55,501	23,962	84,363	31,580
Clinical research services	1,700	31,673	2,050	31,673
Total revenues	102,011	103,400	197,049	223,886
Costs and expenses:
Cost of revenues	338,203	409,463	954,629	718,734
Research and development	981,715	4,076,414	5,261,545	7,284,478
Selling and marketing	615,019	3,129,036	2,023,004	6,186,588
General and administrative	4,059,133	2,468,732	6,255,772	6,472,979
Restructuring Charges	(3,806)	0	1,715,998	0
Total operating expenses	5,990,264	10,083,645	16,210,948	20,662,779
Loss from operations	(5,888,253)	(9,980,245)	(16,013,899)	(20,438,893)
Net interest expense	(431,871)	(274,909)	(861,268)	(612,529)
Gain (loss) from change in fair value of derivative financial instruments—warrants	(71,428)	52,876	484,078	586,626
Gain (Loss) on Extinguishment of Debt	(1,655,825)	0	(1,655,825)	0
Other income, net	1,566	0	1,566	0
Net loss	(8,045,811)	(10,202,278)	(18,045,348)	(20,464,796)
Preferred stock dividend	(6,060)	(6,060)	(12,120)	(12,120)
Net loss attributable to common stockholders	$ (8,051,871)	$ (10,208,338)	$ (18,057,468)	$ (20,476,916)
Net loss per common share - basic (in USD per share)	$ (0.26)	$ (0.34)	$ (0.58)	$ (0.69)
Net loss per common share - diluted (in USD per share)	$ (0.26)	$ (0.34)	$ (0.58)	$ (0.70)
Weighted-average shares outstanding — basic	30,991,740	29,958,037	30,976,462	29,856,611
Weighted-average shares outstanding — diluted	30,991,740	29,958,037	30,976,462	30,033,207